Bioversys AG (BIOV) - Net Assets

Latest as of December 2025: CHF59.81 Million CHF ≈ $75.62 Million USD

Based on the latest financial reports, Bioversys AG (BIOV) has net assets worth CHF59.81 Million CHF (≈ $75.62 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF90.64 Million ≈ $114.59 Million USD) and total liabilities (CHF30.82 Million ≈ $38.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BIOV asset base for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF59.81 Million
% of Total Assets	65.99%
Annual Growth Rate	460.58%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

Bioversys AG - Net Assets Trend (2024–2025)

This chart illustrates how Bioversys AG's net assets have evolved over time, based on quarterly financial data. Check Bioversys AG tangible book value ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Bioversys AG (2024–2025)

The table below shows the annual net assets of Bioversys AG from 2024 to 2025. For live valuation and market cap data, see market cap of Bioversys AG.

Year	Net Assets	Change
2025-12-31	CHF59.81 Million ≈ $75.62 Million	+459.92%
2024-12-31	CHF10.68 Million ≈ $13.50 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Bioversys AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2078500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	CHF160.94 Million	269.08%
Total Equity	CHF59.81 Million	100.00%

Bioversys AG Competitors by Market Cap

The table below lists competitors of Bioversys AG ranked by their market capitalization.

Company	Market Cap
Petronor E&P Ltd OL:PNOR	$161.48 Million
Shaniv TA:SHAN	$161.50 Million
Bonny Worldwide Ltd TW:8467	$161.55 Million
Ligitek Electronics Co Ltd TWO:8111	$161.55 Million
Magnate Technology Co Ltd TWO:4541	$161.34 Million
Texaf SA BR:TEXF	$161.33 Million
AAPICO Hitech Public Company Limited BK:AH	$161.32 Million
ES Cube Co. Ltd KQ:050120	$161.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bioversys AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 10,682,000 to 59,811,000, a change of 49,129,000 (459.9%).
Net loss of 21,830,000 reduced equity.
New share issuances of 76,843,000 increased equity.
Other factors decreased equity by 5,884,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CHF-21.83 Million	-36.5%
Share Issuances	CHF76.84 Million	+128.48%
Other Changes	CHF-5.88 Million	-9.84%
Total Change	CHF-	459.92%

Book Value vs Market Value Analysis

This analysis compares Bioversys AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 15.39x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2024-12-31	CHF1.81	CHF27.80	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bioversys AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -36.50%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -2728.75%
• Asset Turnover: 0.01x
• Equity Multiplier: 1.52x
Recent ROE (-36.50%) is above the historical average (-105.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2024	-175.24%	0.00%	0.00x	3.27x	CHF-19.79 Million
2025	-36.50%	-2728.75%	0.01x	1.52x	CHF-27.81 Million

Industry Comparison

This section compares Bioversys AG's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $480,482,898
Average return on equity (ROE) among peers: -110.54%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Bioversys AG (BIOV)	CHF59.81 Million	-175.24%	0.52x	$161.41 Million
Addex Therapeutics Ltd (ADXN)	$4.91 Million	-423.46%	0.69x	$6.98 Million
Bachem Holding AG (BANB)	$1.12 Billion	10.23%	0.16x	$5.42 Billion
BB Biotech AG (BION)	$2.78 Billion	20.81%	0.00x	$2.48 Billion
Basilea Pharmaceutica AG (BSLN)	$97.73 Million	-123.54%	1.11x	$686.09 Million
Idorsia Ltd (IDIA)	$164.35 Million	-300.98%	5.11x	$1.03 Billion
MINDMAZE THERAPEUTICS HOLDING SA (MMTX)	$38.34 Million	-25.84%	0.34x	$31.32 Million
Molecular Partners AG (MOLN)	$91.70 Million	-40.39%	0.69x	$145.86 Million
Newron Pharmaceuticals SpA (NWRN)	$6.58 Million	-97.87%	1.06x	$297.11 Million
Relief Therapeutics Holding AG (RLF)	$20.95 Million	-13.78%	0.48x	$36.33 Million

About Bioversys AG

SW:BIOV Switzerland Biotechnology

Market Cap

$205.54 Million

CHF162.57 Million CHF

Market Cap Rank

#17351 Global

#176 in Switzerland

Share Price

CHF27.80

Change (1 day)

+2.96%

52-Week Range

CHF21.50 - CHF34.40

All Time High

CHF36.30